Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Ur Energy NYSEAMERICAN:URG$1.80 -0.03 (-1.37%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$709.23 millionConsensus RatingBuyConsensus Price Target$2.50 (+39.3% Upside)Volume4.98 million sharesAverage Volume8.90 million sharesToday's Range$1.77▼$1.90 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. iBio NASDAQ:IBIO$1.64 -0.02 (-0.90%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBioMarket Capitalization$59.41 millionConsensus RatingBuyConsensus Price Target$4.75 (+188.8% Upside)Volume79,075 sharesAverage Volume1.49 million sharesToday's Range$1.62▼$1.673. Inhibikase Therapeutics NASDAQ:IKT$1.96 -0.08 (-3.69%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase TherapeuticsMarket Capitalization$258.18 millionConsensus RatingBuyConsensus Price Target$5.50 (+181.3% Upside)Volume50,733 sharesAverage Volume1.54 million sharesToday's Range$1.98▼$2.044. Peraso NASDAQ:PRSO$0.98 -0.40 (-29.20%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Peraso Inc, a fabless semiconductor company, develops, markets, and sells semiconductor devices and modules. The company's products include millimeter wavelength (mmWave) ICs, including baseband IC, various mmWave radio frequency, integrated circuits, as well as associated antenna technology; and mmWave antenna modules. More about PerasoMarket Capitalization$12.34 millionConsensus RatingBuyConsensus Price Target$3.00 (+207.1% Upside)Volume3.11 million sharesAverage Volume6.09 million sharesToday's Range$0.92▼$1.075. Biomea Fusion NASDAQ:BMEA$1.58 +0.01 (+0.83%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$114.45 millionConsensus RatingModerate BuyConsensus Price Target$8.29 (+423.4% Upside)Volume138,527 sharesAverage Volume1.40 million sharesToday's Range$1.54▼$1.596. Autolus Therapeutics NASDAQ:AUTL$1.56 -0.02 (-0.95%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$416.51 millionConsensus RatingModerate BuyConsensus Price Target$8.50 (+443.1% Upside)Volume234,167 sharesAverage Volume1.72 million sharesToday's Range$1.54▼$1.587. Real Brokerage NASDAQ:REAX$1.88 -0.03 (-1.32%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.The Real Brokerage Inc, together with its subsidiaries, operates as a real estate technology company in the United States and Canada. More about Real BrokerageMarket Capitalization$400.31 millionConsensus RatingModerate BuyConsensus Price Target$5.69 (+203.3% Upside)Volume854,909 sharesAverage Volume2.12 million sharesToday's Range$1.85▼$1.928. Palisade Bio NASDAQ:PALI$1.96 +0.03 (+1.29%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade BioMarket Capitalization$328.99 millionConsensus RatingModerate BuyConsensus Price Target$10.20 (+419.1% Upside)Volume936,050 sharesAverage Volume4.28 million sharesToday's Range$1.89▼$1.989. Tenaya Therapeutics NASDAQ:TNYA$1.01 +0.02 (+1.69%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya TherapeuticsMarket Capitalization$220.26 millionConsensus RatingModerate BuyConsensus Price Target$4.00 (+294.1% Upside)Volume1.99 million sharesAverage Volume4.26 million sharesToday's Range$0.97▼$1.0710. MediciNova NASDAQ:MNOV$1.39 -0.02 (-1.42%) As of 10:34 AM Eastern This is a fair market value price provided by Massive. Learn more.MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More about MediciNovaMarket Capitalization$68.42 millionConsensus RatingModerate BuyConsensus Price Target$7.50 (+439.6% Upside)Volume23,261 sharesAverage Volume58,830 sharesToday's Range$1.39▼$1.4011. Compass Therapeutics NASDAQ:CMPX$1.88 +0.05 (+2.46%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass TherapeuticsMarket Capitalization$337.67 millionConsensus RatingModerate BuyConsensus Price Target$13.60 (+625.3% Upside)Volume884,806 sharesAverage Volume5.44 million sharesToday's Range$1.81▼$1.8812. Nano-X Imaging NASDAQ:NNOX$1.62 -0.02 (-0.92%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X ImagingMarket Capitalization$112.39 millionConsensus RatingModerate BuyConsensus Price Target$5.00 (+209.6% Upside)Volume299,002 sharesAverage Volume1.26 million sharesToday's Range$1.59▼$1.6313. Senti Biosciences NASDAQ:SNTI$1.01 -0.01 (-0.69%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. More about Senti BiosciencesMarket Capitalization$31.45 millionConsensus RatingModerate BuyConsensus Price Target$8.50 (+739.1% Upside)Volume26,609 sharesAverage Volume191,732 sharesToday's Range$0.99▼$1.0314. DeFi Technologies NASDAQ:DEFT$0.72 -0.02 (-2.44%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.DeFi Technologies, Inc engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. More about DeFi TechnologiesMarket Capitalization$278.49 millionP/E Ratio4.22Consensus RatingModerate BuyConsensus Price Target$2.25 (+212.5% Upside)Volume1.07 million sharesAverage Volume5.55 million shares15. enCore Energy NASDAQ:EU$1.62 -0.06 (-3.29%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore EnergyMarket Capitalization$313.67 millionConsensus RatingModerate BuyConsensus Price Target$3.83 (+137.4% Upside)Volume588,797 sharesAverage Volume3.03 million sharesToday's Range$1.59▼$1.6616. Metagenomi NASDAQ:MGX$1.36 +0.01 (+0.37%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More about MetagenomiMarket Capitalization$51.02 millionConsensus RatingModerate BuyConsensus Price Target$9.00 (+564.2% Upside)Volume78,293 sharesAverage Volume229,342 sharesToday's Range$1.30▼$1.3517. Humacyte NASDAQ:HUMA$0.96 -0.04 (-4.20%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about HumacyteMarket Capitalization$212.70 millionConsensus RatingModerate BuyConsensus Price Target$7.71 (+705.2% Upside)Volume1.50 million sharesAverage Volume6.25 million sharesToday's Range$0.94▼$0.9818. Milestone Pharmaceuticals NASDAQ:MIST$1.90 -0.01 (-0.26%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. More about Milestone PharmaceuticalsMarket Capitalization$226.72 millionConsensus RatingModerate BuyConsensus Price Target$7.50 (+295.8% Upside)Volume280,366 sharesAverage Volume2.20 million sharesToday's Range$1.89▼$1.9719. Rani Therapeutics NASDAQ:RANI$1.06 -0.02 (-1.40%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani TherapeuticsMarket Capitalization$130.49 millionConsensus RatingModerate BuyConsensus Price Target$7.80 (+639.3% Upside)Volume251,488 sharesAverage Volume1.06 million sharesToday's Range$1.02▼$1.0920. PepGen NASDAQ:PEPG$1.72 +0.02 (+1.18%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. More about PepGenMarket Capitalization$120.01 millionConsensus RatingModerate BuyConsensus Price Target$11.80 (+586.0% Upside)Volume252,908 sharesAverage Volume1.20 million sharesToday's Range$1.65▼$1.7521. ProQR Therapeutics NASDAQ:PRQR$1.60 -0.01 (-0.43%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR TherapeuticsMarket Capitalization$168.89 millionConsensus RatingModerate BuyConsensus Price Target$7.25 (+352.3% Upside)Volume118,740 sharesAverage Volume522,093 sharesToday's Range$1.57▼$1.6322. Skye Bioscience NASDAQ:SKYE$0.86 -0.02 (-2.61%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. More about Skye BioscienceMarket Capitalization$30.11 millionConsensus RatingModerate BuyConsensus Price Target$9.80 (+1,043.5% Upside)Volume19,545 sharesAverage Volume472,433 sharesToday's Range$0.85▼$0.9023. HeartBeam NASDAQ:BEAT$0.92 +0.03 (+3.52%) As of 10:43 AM Eastern This is a fair market value price provided by Massive. Learn more.BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. More about HeartBeamMarket Capitalization$37.72 millionConsensus RatingModerate BuyConsensus Price Target$4.80 (+422.9% Upside)Volume151,384 sharesAverage Volume1.32 million sharesToday's Range$0.91▼$0.9424. MDxHealth NASDAQ:MDXH$1.96 -0.03 (-1.51%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More about MDxHealthMarket Capitalization$97.02 millionConsensus RatingModerate BuyConsensus Price Target$7.75 (+295.4% Upside)Volume89,435 sharesAverage Volume157,168 sharesToday's Range$1.93▼$2.0425. NeuroSense Therapeutics NASDAQ:NRSN$0.85 +0.01 (+1.68%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. More about NeuroSense TherapeuticsMarket Capitalization$27.64 millionConsensus RatingModerate BuyConsensus Price Target$8.50 (+901.2% Upside)Volume7,794 sharesAverage Volume187,484 sharesToday's Range$0.84▼$0.87 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
